Stay updated on Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Sign up to get notified when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.

Latest updates to the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page
- Check2 days agoChange DetectedNew entries appear in the Record History with updates to Study Status and Eligibility across multiple versions, reflecting changes to recruitment and oversight details of the study.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check30 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference12%

- Check38 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0. This signals a software update; no other content changes are indicated.SummaryDifference0.3%

- Check52 days agoChange DetectedUpdated version to v3.0.2 and removed 'Back to Top' link; no substantive changes to core content or critical data.SummaryDifference0.7%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%

- Check66 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries.SummaryDifference12%

Stay in the know with updates to Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.